The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
暂无分享,去创建一个
P Sutcliffe | P Tappenden | S. Paisley | P. Tappenden | P. Sutcliffe | S. Eggington | S Paisley | A Pandor | A. Pandor | S Eggington
[1] M. Brown,et al. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. , 1994, Journal of the National Cancer Institute.
[2] B. Vonen,et al. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] E. Van Cutsem,et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). , 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[4] H. Beger,et al. Surgery of Colorectal Cancer: Surgical Morbidity and Five- and Ten-Year Results in 2400 Patients—Monoinstitutional Experience , 2001, World Journal of Surgery.
[5] U. Pastorino,et al. Oxaliplatin Toxicity Masquerading As Recurrent Colon Cancer , 2022 .
[6] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[7] Owen D Williamson,et al. Determining the sample size in a clinical trial , 2003, The Medical journal of Australia.
[8] S. Petrou,et al. Stabilisation in colorectal cancer. , 1997, International journal of palliative nursing.
[9] C. Moinpour,et al. Quality of life in long term survivors of colorectal cancer , 2002, American Journal of Gastroenterology.
[10] W. Willett,et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. , 2000, Journal of the National Cancer Institute.
[11] S. Faithfull,et al. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. , 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[12] A. Haycox,et al. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. , 2003, Health technology assessment.
[13] J. Macdonald. Continuous low-dose infusion of fluorouracil: is the benefit worth the cost? , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Sargent,et al. Adjuvant therapy for colon cancer--the pace quickens. , 2005, The New England journal of medicine.
[15] J Cowan,et al. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. , 2003, Health technology assessment.
[16] J. Lotz,et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). , 2001, European journal of cancer.
[17] D. Cunningham,et al. Adjuvant therapy in colon cancer: current status and future directions. , 2002, Cancer treatment reviews.
[18] W. Scheithauer,et al. Answering patients' needs: oral alternatives to intravenous therapy. , 2001, The oncologist.
[19] K. Maung. Update on adjuvant trials in the treatment of high-risk colorectal cancer. , 2004, Clinical colorectal cancer.
[20] B. Glimelius,et al. A systematic overview of chemotherapy effects in colorectal cancer. , 2001, Acta oncologica.
[21] P. Fumoleau,et al. The vital role of education and information in patients receiving capecitabine (Xeloda). , 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[22] J. Douillard,et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer , 2005 .
[23] R. Mayer,et al. Two steps forward in the treatment of colorectal cancer. , 2004, The New England journal of medicine.
[24] J. Cassidy,et al. Capecitabine in the treatment of colorectal cancer. , 2005, Future oncology.
[25] P. Loehrer. Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials , 2006 .
[26] R. Labianca,et al. Elderly colorectal cancer patients are under treated , 2004 .
[27] J. Lotz,et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.
[28] R. Gelber,et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. , 1996, Journal of the National Cancer Institute.
[29] Bonnie-Mae Gerbrecht,et al. Implications of capecitabine (Xeloda) for cancer nursing practice. , 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[30] A. Messori,et al. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. , 1996, Journal of clinical gastroenterology.
[31] T. Hickish,et al. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Goldberg,et al. Review article: colorectal cancer chemotherapy. , 2003, Alimentary pharmacology & therapeutics.
[33] G. Peters,et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.
[34] C. Tournigand,et al. The evolving role of oxaliplatin in the management of colorectal cancer , 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[35] T. Conroy,et al. Health-related quality of life in colorectal cancer patients , 2003, Expert review of anticancer therapy.
[36] C. Ko,et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.
[37] S. Payne. A study of quality of life in cancer patients receiving palliative chemotherapy. , 1992, Social science & medicine.
[38] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[39] A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.
[40] R. J. Cersosimo. Oxaliplatin-Associated Neuropathy: A Review , 2005, The Annals of pharmacotherapy.
[41] A. de Gramont,et al. An overview of adjuvant systemic chemotherapy for colon cancer. , 2004, Clinical colorectal cancer.
[42] E. von Elm,et al. Full publication of results initially presented in abstracts. , 2007, The Cochrane database of systematic reviews.
[43] D. Berg. Oxaliplatin: a novel platinum analog with activity in colorectal cancer. , 2003, Oncology nursing forum.
[44] M. Brouwers,et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] H. Au,et al. Systematic review of management of colorectal cancer in elderly patients. , 2003, Clinical colorectal cancer.
[46] J. Hardcastle,et al. Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.
[47] M. Fey. [Adjuvant therapy for colon cancer]. , 2000, Schweizerische medizinische Wochenschrift.
[48] P. Hoff,et al. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). , 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[49] A. Figer,et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] P. Bhargava,et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin , 2004, Cancer.
[51] W. Scheithauer,et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] K. Maung. Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer. , 2003, Clinical colorectal cancer.
[53] R. Labianca,et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] J. Cassidy,et al. Oxaliplatin-related side effects: characteristics and management. , 2002, Seminars in oncology.
[55] H O Dickinson,et al. Cancer trends in England and Wales , 2000, BMJ : British Medical Journal.
[56] A. Neugut,et al. Survival Associated with 5-FluorouracilBased Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon Cancer , 2002, Annals of Internal Medicine.
[57] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[58] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[59] E. Winer,et al. Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.
[60] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[61] T. Hickish,et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years , 2005 .
[62] H. Hochster,et al. Oxaliplatin: practical guidelines for administration. , 2004, Clinical journal of oncology nursing.
[63] Stephen B Gruber,et al. The Genetics of Colorectal Cancer , 2006, Annals of Internal Medicine.
[64] D. Semmler,et al. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. , 2003, Hepato-gastroenterology.
[65] R. Porschen,et al. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion , 2005, International Journal of Colorectal Disease.
[66] J. Wardle,et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial , 2002, The Lancet.
[67] M. Postma,et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. , 2004, Clinical therapeutics.
[68] S. Bingham,et al. Diet and the prevention of cancer , 1998, BMJ.
[69] C. Walko,et al. Capecitabine: a review. , 2005, Clinical therapeutics.
[70] S. Cha,et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] C. la Vecchia,et al. Aspirin and cancer risk: an update to 2001 , 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[72] V. Kataja,et al. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. , 2005, Annals of Oncology.
[73] W. Willett. The search for the causes of breast and colon cancer , 1989, Nature.
[74] A. Messori,et al. Median versus mean lifetime survival in the analysis of survival data. , 1997, Haematologica.
[75] N. Wolmark,et al. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. , 2004, Journal of the National Cancer Institute.
[76] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[77] Marc Buyse,et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] J. Davis,et al. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. , 2000, Archives of surgery.
[79] A. Grothey. Oxaliplatin-safety profile: neurotoxicity. , 2003, Seminars in oncology.
[80] Catherine Beverley,et al. Systematic reviews to support evidence-based medicine: how to review and apply findings of healthcare research , 2004 .
[81] T. Hickish,et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[82] Bonnie-Mae Gerbrecht. Current Canadian Experience With Capecitabine: Partnering With Patients to Optimize Therapy , 2003, Cancer nursing.
[83] J. Potter,et al. Reconciling the epidemiology, physiology, and molecular biology of colon cancer. , 1992, JAMA.
[84] S. Barni,et al. Oxaliplatin in colon cancer. , 2004, The New England journal of medicine.
[85] E. Hughes,et al. Carcinoma of the Colon Cancer Specific Long‐term Survival. A Series of 615 Patients Treated by One Surgeon , 1980, Annals of surgery.
[86] G. Reddy. Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial. , 2004, Clinical colorectal cancer.
[87] David K Whynes,et al. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer , 2004, BMJ : British Medical Journal.
[88] E. Bria,et al. Skin testing and hypersensitivity reactions to oxaliplatin. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[89] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] D. Cunningham,et al. Chemotherapy in colorectal cancer: new options and new challenges. , 2002, British medical bulletin.
[91] A. Gramont,et al. Colorectal cancer: Integrating oxaliplatin , 2003, Current treatment options in oncology.
[92] D. Cunningham,et al. Oxaliplatin for colorectal cancer in the United States: better late than never. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] R. Labianca,et al. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[94] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[95] T. Hickish,et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer , 2003, British Journal of Cancer.
[96] A. Sobrero. Scheduling of fluorouracil: a forget-me-not in the jungle of doublets. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] P. D. de Souza. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. , 1993, The Medical journal of Australia.
[98] J. Corner. The role of nurse-led care in cancer management. , 2003, The Lancet. Oncology.
[99] J. Cairns,et al. The estimation of marginal time preference in a UK-wide sample (TEMPUS) project. , 2000, Health technology assessment.
[100] F. Lévi,et al. Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases , 2001, Annals of Surgical Oncology.
[101] W. Scheithauer,et al. Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts) , 2004 .
[102] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[103] V. Gebski,et al. Inclusion of patients in clinical trial analysis: the intention‐to‐treat principle , 2003, The Medical journal of Australia.
[104] L. Aaltonen,et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.
[105] J A Lewis,et al. Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.
[106] E. Hughes,et al. Comparative results of surgical management of single carcinomas of the colon and rectum: A series of 1939 patients managed by one surgeon , 1981, The British journal of surgery.
[107] Douglas G Altman,et al. Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.
[108] D. Sebag‐Montefiore,et al. Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[109] C. Begg,et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.
[110] G. Weiss,et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] N. Wolmark,et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 , 2005 .
[112] R. Labianca,et al. Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. , 2004, Journal of the National Cancer Institute.
[113] J. Tabernero,et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer , 2005 .
[114] E. Saad,et al. Incidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution Experience , 2002, Cancer investigation.
[115] D. I. Cook,et al. Subgroup analysis in clinical trials , 2004, The Medical journal of Australia.
[116] A. Neugut,et al. Management of Colorectal Cancer in Elderly Patients , 2004, Drugs & aging.
[117] Markus Abt,et al. Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.
[118] E. Warner,et al. Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] R. Dittus,et al. Utility valuations for outcome states of colorectal cancer , 1999, American Journal of Gastroenterology.
[120] N Urban,et al. Quality of life in survivors of colorectal carcinoma , 2000, Cancer.
[121] N. Bansback,et al. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. , 2002, Health technology assessment.
[122] A. Bottomley,et al. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. , 2004, European journal of cancer.
[123] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .
[124] Hans-Peter,et al. Biochemical epidemiology of colon cancer: effect of types of dietary fiber on fecal mutagens, acid, and neutral sterols in healthy subjects. , 1989, Cancer research.
[125] H. Rockette,et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.